(Supplemental Methods) Oral tranexamic acid use in melasma patients lacks association with thromboembolism: A TriNetX retrospective analysis

Supplemental Methods:
Regarding the manuscript “Oral tranexamic acid use in melasma patients lacks association with thromboembolism: A TriNetX retrospective analysis”
The present study reinforces the safety of 650mg oTXA as an adjunctive therapy in melasma, with no observed increase in short-term thromboembolic risk among appropriately screened patients. Clinician assessment of thromboembolic risk factors remains essential, and additional research is necessary to clarify long-term risks and cumulative dose thresholds.